Evaluación de la enfermedad de membrana hialina en recien nacidos
Evaluation of hyaline membrane disease in newborns
Barra lateral del artículo
PDF
FLIP
Cómo citar
Perna, J. A., Pérez H., I., Ramírez, J. E., & Varela D, M. E. (2002). Evaluación de la enfermedad de membrana hialina en recien nacidos. Revista Repertorio De Medicina Y Cirugía, 11(2), 7–20. https://doi.org/10.31260/RepertMedCir.v11.n2.2002.277
Sección
Artículo de revisión
Términos de Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Contenido principal del artículo
Resumen
Para valorar la incidencia de la enfermedad de membrana hialina (EMH), caracterizar la población de riesgo, evaluar el tratamiento instaurado y las complicaciones más frecuentes en recien nacidos, se realizó un estudio retrospectivo descriptivo en los pacientes que ingresaron a la Unidad de Cuidado lntensivo Neonatal (UCIN) del Hospital de San Jose. Se incluyeron todos los pacientes en los cuales se diagnosticó clínica y paraclínicamente EMH, quienes fueron distribuidos en cuatro grupos seg(rn el peso. Los datos recopilados mostraron una mayor incidencia de EMH en los menores de 1.000 g (63%), en comparación con los mayores de 1.500 g (5%). La complicación encontrada con mayor frecuencia fue la enfermedad pulmonar crónica del recien nacido(24%), seguida del neumotorax (21 %). En el estudio, la mortalidad fue de (33,5%), la cual es mayor a la reportada en la literatura mundial, posiblemente secundaria a la alta incidencia de complicaciones, sobre todo en los pacientes menores de 1.000 g. Finalmente se plantean estrategias de manejo para disminuir la morbimortalidad de los pacientes con EMH.
Palabras clave:
Descargas
Los datos de descargas todavía no están disponibles.
Detalles del artículo
Referencias
1. Correa J, Pifieros JG, Gómez A y col. Síndrome de Dificultad Respiratoria del Recién Nacido. UCIN 2000;1: 22-9.
2. Taeusch W, Ballard R. Avery's Diseases of the Newborn. Séptima Edición, W.B. Saunders Company 1998. Pág: 602- 612.
3. Fanaroff A, Martin R, y col. Neonatal. Perinatal Medicine, Sexta Edición, Editorial Mosby, 1998: 1018-29.
4. Hack M, Very low birthweight outcomes of the NICHD neonatal network November 1989 - October 1990, Am J Obst Gynecol 172:457.
5. Taussing, Linn M, Landau Louis, Pediatric Respiratory Medicine, 1999. Editorial Mosby. Primera Edición. Páginas 464- 468.
6. Tapia J, Ventura P, Manual de Neonatología. Segunda Edición. Editorial Mediterráneo. 2000. Capítulo 27, Páginas 244-247.
7. Lee K, Khoshnood B, Wall S. Trend in mortality from respiratory distrés syndrome in the Unites States, 1.970-1.995. J Ped 1999; 134: 4.
8. Ranganathan D, Wall S y col. Racial differences in respiratory-related neonatal mortality among very low birth weight infants. J Ped 2000;136: 4.
9. Abbasi S, Hirsch D, Davis J. Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am Jr of Obstetrics and Gynecology 2000; 182: 5.
10. Van Golde LMG, The pulmonary surfactant system: biochemical aspects and functional significance, Physiol Rew 1988, 68:374.
11. Kattwinkel J, Bloom B, Delmore P. High-versus low trheshold surfactant retreatment for neonatal Respiratory Distrés Syndrome. Pediatrics 2000; 106: 2.
12. Hallman M, Phosphatidylinositol and phosphatidylglycerol in amniotic fluid: indices of lung maturity. Am J Obstet Gynecol 1976; 125:613.
13. Hallman M, Role of myo-inositol in the synthesis of phosphatidylglycerol and phosphatidylinositol in the lung: Biochem Biophys Res Commun 1980; 92:1151.
14. Ikegami M, Surfactant protein A metabolism in preterm vetiled lambs, Am J Physiol 1992; 262:765.
15. Weaver TE, Function and regulation of expression of pulmonary surfactant-associated proteins, Biochem Jr 1991; 273:249.
16. McNeely TB, Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages, J lnfect Dis 1993; 167:91.
17. O'Brodovich H, Bicarbonate concentration in rhesus monkey and guinea pig fetal lung fluid, Am Rev Respir Dis 1992; 146:1613.
18. Possmayer F: The role of surfactant-associated proteins, Am Rev Respir Dis 1990;142:749.
19. Hamvas A, Surfactant protein B deficiency: antenatal diag- nosis and prospective treatment with surfactant replacement, J Pediatr 1994;125:356.
20. DeMello DE, Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. J Pediatr 1994; 125:43.
21. Clements JA, Kinetics of surface active material in fetal lung. In Hodson WA, editor: Development of the lung, New York, 1977; 543-544.
22. Gluck L, The interpretation and significance of the lecithin/ sphingomyelin ratio in amniotic fluid. Am J Obstet Gynecol 1974; 120:142.
23. Kulovich MV, The lung profile. Am J Obstet Gynecol 1979; 135:57.
24. Pryhuber GS, Ontogeny of surfactant proteins A and B in human amniotic fluid as indices of fetal lung maturity, Ped Res 1991; 30:597.
25. Jobe AH, et al: Surfactant for the treatment of respiratory distress syndrome, Am Rev Respir Dis 1987; 136:1256.
26. Hallman M, Surfactant protein A , phosphatidylcoline, and surfactant, inhibitors in epithelial lining fluid. Am Rev Resp Dis 1994; 144:1376.
27. Glatz T, Metabolism of exogenously administered natural surfactant in newborn lambs, Pediatr Res 1982; 16:711.
28. Garland J, Alex C, Pauly T y col. A three day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates. Pediatrics 1999; 104: 1.
29. Sinkin R, Dweck H, Horgan M y col. Early dexamethason attempting to prevent chronic lung disease. Pediatrcis 2000; 105: 3.
30. American Academy or Pediatrics. Surfactant replacement therapy for Respiratory Distrés Syndrome. Pediatrics 1999; 103: 3.
31. Jobe HA, et al:Catabolism and recycling of surfactant: In Robertson B, et al , editors: The pulmonary surfactant system, Amsterdam, 1992.
32. Newman B. Imaging of medical disease of the newborn lung. Radiologic Clinics of North America 1999; 37: 6.
33. Ablow RC, A comparison of early onset group B streptococal neonatal infection and the respiratory distrés syndrome of the newborn. N Engl J Med 1976; 294:65.
34. Mariani G, Cifuentes J, Carlo W. Randomized trial of permissive hypercapnia in preterm infants. Pediatrics 1999; 104: 5.
35. McEvoy C, Bowling S, Williamson K y col. Timing of antenatal corticosteroids an neonata] pulmonary mechanics. American Journal of Obstetrics and Gynecology 2000; 183:4.
36. Klaus, Marshall, Fanaroff, Avroy: Care of the high- risk neonate. Novena Edición 1993.
37. Fujiwara T, Artificial surfactant therapy in hyaline membrane disease, Lancet 1980; 1:55.
38. Didziulis L, Perna J, Varela M, Martínez L, Mateus M, Campo M y Col, Uso de Eritropoyetina en Pretérminos, Hospital de San José 1998.
39. Hallman M, Exogenous human surfactant for treatment of severe respiratory distrés syndrome: a randomized prospective clinical trial, J Pediatr 1985;106:963.
40. Phibbs RH, Inictial clinical rial of EXOSURF, a proteinfree synthetic surfactant, for he prophylaxis and early treatment of hyaline membrane disease, Pediatrics 1991; 88:1.
41. Clinicas de Perinatologia. Controversias en el cuidado pulmonar neonatal, Editorial McGraw-Hill 1998, Pág 17-35, 85-90,105-122, 195-220.
42. Yamaguchi N, Togari H, Suzuki S. Apparatus and techniques. Critical Care Medicine 2000; 28: 5.
43. Clark R, Slutsky A, Gerstmann D. Lung protective strategies of ventilation in the neonate. Pediatrics 2000; 105: 1.
44. Lemons J, Blackmon L, Danto W y col. Use of Inhaled Nitric Oxide. AAP. Pediatrices 2000; 106: 2.
45. Rimensberger P, Beghetti M, Hanquinet S y col. First intention High-frequency Oscillation with early lung volume optimization improves pulmonary outcome in very low birth weight infants with SDR. Pediatrics 2000; 105: 6.
46. Farrell P, Fiascone J. Bronchopulmonary Dysplasia in the 1990s. Curr Probl Pediatr 1997: 133 - 63.
47. Bancalari E. Comentario sobre la Displasia Broncopulmonar. Neonatología Práctica 1998. Tercera Edición: 246-249.
48. Shenai J, Mellen B, Chytil F. Vitamin A Status and Postnatal Dexamethasone Treatment in Bronchopulmonary Dysplasia. Pediatrics 2000, 1-6; 3.
49. Montenegro M, Amaya L, Retinopatia de la prematurez. Actualizaciones Pediatricas 1998,8; 3:96-100
50. Volpe J, Neurology of the newborn. Tercera edición. Filadelfia: W.B. Saunders, 1995, cap,11.
51. Cloherty J, Stark A. Manual de Cuidados Neonatales. Tercera edición, Barcelona: Editorial Masson 1999, Cap,6,24,2
52. Couser R, Neurodevelopmental follow-up at 36 months 's corrected age of preterm infants treated with prophylactic indomethacin. Arc Pediatr Adolesc Med 2000, 154; 6: 598- 602.
53. Angerio A, Kot P. Closure of the ductus arteriosus new insights for critical care. Critical Care Nursing Quarterly 1998, 20; 4: 80-85.
54. Pacifico L, Panero A, Roggini M. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population. Pediatr Infect Dis J 1997, 16; 579-86.
2. Taeusch W, Ballard R. Avery's Diseases of the Newborn. Séptima Edición, W.B. Saunders Company 1998. Pág: 602- 612.
3. Fanaroff A, Martin R, y col. Neonatal. Perinatal Medicine, Sexta Edición, Editorial Mosby, 1998: 1018-29.
4. Hack M, Very low birthweight outcomes of the NICHD neonatal network November 1989 - October 1990, Am J Obst Gynecol 172:457.
5. Taussing, Linn M, Landau Louis, Pediatric Respiratory Medicine, 1999. Editorial Mosby. Primera Edición. Páginas 464- 468.
6. Tapia J, Ventura P, Manual de Neonatología. Segunda Edición. Editorial Mediterráneo. 2000. Capítulo 27, Páginas 244-247.
7. Lee K, Khoshnood B, Wall S. Trend in mortality from respiratory distrés syndrome in the Unites States, 1.970-1.995. J Ped 1999; 134: 4.
8. Ranganathan D, Wall S y col. Racial differences in respiratory-related neonatal mortality among very low birth weight infants. J Ped 2000;136: 4.
9. Abbasi S, Hirsch D, Davis J. Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am Jr of Obstetrics and Gynecology 2000; 182: 5.
10. Van Golde LMG, The pulmonary surfactant system: biochemical aspects and functional significance, Physiol Rew 1988, 68:374.
11. Kattwinkel J, Bloom B, Delmore P. High-versus low trheshold surfactant retreatment for neonatal Respiratory Distrés Syndrome. Pediatrics 2000; 106: 2.
12. Hallman M, Phosphatidylinositol and phosphatidylglycerol in amniotic fluid: indices of lung maturity. Am J Obstet Gynecol 1976; 125:613.
13. Hallman M, Role of myo-inositol in the synthesis of phosphatidylglycerol and phosphatidylinositol in the lung: Biochem Biophys Res Commun 1980; 92:1151.
14. Ikegami M, Surfactant protein A metabolism in preterm vetiled lambs, Am J Physiol 1992; 262:765.
15. Weaver TE, Function and regulation of expression of pulmonary surfactant-associated proteins, Biochem Jr 1991; 273:249.
16. McNeely TB, Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages, J lnfect Dis 1993; 167:91.
17. O'Brodovich H, Bicarbonate concentration in rhesus monkey and guinea pig fetal lung fluid, Am Rev Respir Dis 1992; 146:1613.
18. Possmayer F: The role of surfactant-associated proteins, Am Rev Respir Dis 1990;142:749.
19. Hamvas A, Surfactant protein B deficiency: antenatal diag- nosis and prospective treatment with surfactant replacement, J Pediatr 1994;125:356.
20. DeMello DE, Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. J Pediatr 1994; 125:43.
21. Clements JA, Kinetics of surface active material in fetal lung. In Hodson WA, editor: Development of the lung, New York, 1977; 543-544.
22. Gluck L, The interpretation and significance of the lecithin/ sphingomyelin ratio in amniotic fluid. Am J Obstet Gynecol 1974; 120:142.
23. Kulovich MV, The lung profile. Am J Obstet Gynecol 1979; 135:57.
24. Pryhuber GS, Ontogeny of surfactant proteins A and B in human amniotic fluid as indices of fetal lung maturity, Ped Res 1991; 30:597.
25. Jobe AH, et al: Surfactant for the treatment of respiratory distress syndrome, Am Rev Respir Dis 1987; 136:1256.
26. Hallman M, Surfactant protein A , phosphatidylcoline, and surfactant, inhibitors in epithelial lining fluid. Am Rev Resp Dis 1994; 144:1376.
27. Glatz T, Metabolism of exogenously administered natural surfactant in newborn lambs, Pediatr Res 1982; 16:711.
28. Garland J, Alex C, Pauly T y col. A three day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates. Pediatrics 1999; 104: 1.
29. Sinkin R, Dweck H, Horgan M y col. Early dexamethason attempting to prevent chronic lung disease. Pediatrcis 2000; 105: 3.
30. American Academy or Pediatrics. Surfactant replacement therapy for Respiratory Distrés Syndrome. Pediatrics 1999; 103: 3.
31. Jobe HA, et al:Catabolism and recycling of surfactant: In Robertson B, et al , editors: The pulmonary surfactant system, Amsterdam, 1992.
32. Newman B. Imaging of medical disease of the newborn lung. Radiologic Clinics of North America 1999; 37: 6.
33. Ablow RC, A comparison of early onset group B streptococal neonatal infection and the respiratory distrés syndrome of the newborn. N Engl J Med 1976; 294:65.
34. Mariani G, Cifuentes J, Carlo W. Randomized trial of permissive hypercapnia in preterm infants. Pediatrics 1999; 104: 5.
35. McEvoy C, Bowling S, Williamson K y col. Timing of antenatal corticosteroids an neonata] pulmonary mechanics. American Journal of Obstetrics and Gynecology 2000; 183:4.
36. Klaus, Marshall, Fanaroff, Avroy: Care of the high- risk neonate. Novena Edición 1993.
37. Fujiwara T, Artificial surfactant therapy in hyaline membrane disease, Lancet 1980; 1:55.
38. Didziulis L, Perna J, Varela M, Martínez L, Mateus M, Campo M y Col, Uso de Eritropoyetina en Pretérminos, Hospital de San José 1998.
39. Hallman M, Exogenous human surfactant for treatment of severe respiratory distrés syndrome: a randomized prospective clinical trial, J Pediatr 1985;106:963.
40. Phibbs RH, Inictial clinical rial of EXOSURF, a proteinfree synthetic surfactant, for he prophylaxis and early treatment of hyaline membrane disease, Pediatrics 1991; 88:1.
41. Clinicas de Perinatologia. Controversias en el cuidado pulmonar neonatal, Editorial McGraw-Hill 1998, Pág 17-35, 85-90,105-122, 195-220.
42. Yamaguchi N, Togari H, Suzuki S. Apparatus and techniques. Critical Care Medicine 2000; 28: 5.
43. Clark R, Slutsky A, Gerstmann D. Lung protective strategies of ventilation in the neonate. Pediatrics 2000; 105: 1.
44. Lemons J, Blackmon L, Danto W y col. Use of Inhaled Nitric Oxide. AAP. Pediatrices 2000; 106: 2.
45. Rimensberger P, Beghetti M, Hanquinet S y col. First intention High-frequency Oscillation with early lung volume optimization improves pulmonary outcome in very low birth weight infants with SDR. Pediatrics 2000; 105: 6.
46. Farrell P, Fiascone J. Bronchopulmonary Dysplasia in the 1990s. Curr Probl Pediatr 1997: 133 - 63.
47. Bancalari E. Comentario sobre la Displasia Broncopulmonar. Neonatología Práctica 1998. Tercera Edición: 246-249.
48. Shenai J, Mellen B, Chytil F. Vitamin A Status and Postnatal Dexamethasone Treatment in Bronchopulmonary Dysplasia. Pediatrics 2000, 1-6; 3.
49. Montenegro M, Amaya L, Retinopatia de la prematurez. Actualizaciones Pediatricas 1998,8; 3:96-100
50. Volpe J, Neurology of the newborn. Tercera edición. Filadelfia: W.B. Saunders, 1995, cap,11.
51. Cloherty J, Stark A. Manual de Cuidados Neonatales. Tercera edición, Barcelona: Editorial Masson 1999, Cap,6,24,2
52. Couser R, Neurodevelopmental follow-up at 36 months 's corrected age of preterm infants treated with prophylactic indomethacin. Arc Pediatr Adolesc Med 2000, 154; 6: 598- 602.
53. Angerio A, Kot P. Closure of the ductus arteriosus new insights for critical care. Critical Care Nursing Quarterly 1998, 20; 4: 80-85.
54. Pacifico L, Panero A, Roggini M. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population. Pediatr Infect Dis J 1997, 16; 579-86.
Citado por
